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ABSTRACT
XRCC1 plays a central role in mammalian single-
strand break repair. Although it has no enzymatic
activity of its own, it stimulates the activities of
polynucleotide kinase/phosphatase (PNKP), and
this function is enhanced by protein kinase CK2
mediated phosphorylation of XRCC1. We have
previously shown that non-phosphorylated XRCC1
stimulates the kinase activity of PNKP by increasing
the turnover of PNKP. Here we extend our
analysis of the XRCC1-PNKP interaction taking
into account the phosphorylation of XRCC1. We
demonstrate that phosphorylated and non-
phosphorylated XRCC1 interact with different
regions of PNKP. Phosphorylated XRCC1 binds
with high affinity (Kd=3.5nM and 1:1 stoichiometry)
to the forkhead associated (FHA) domain, while non-
phosphorylated XRCC1 binds to the catalytic
domain of PNKP with lower affinity (Kd=43.0nM
and 1:1 stoichiometry). Under conditions of limited
enzyme concentration both forms of XRCC1
enhance the activities of PNKP, but the effect is
more pronounced with phosphorylated XRCC1,
particularly for the kinase activity of PNKP.
The stimulatory effect of phosphorylated XRCC1
on PNKP can be totally inhibited by the pres-
ence of excess FHA domain polypeptide, but
non-phosphorylated XRCC1 is not susceptible to
competition by the FHA domain. Thus, XRCC1 can
stimulate PNKP by two independent mechanisms.
INTRODUCTION
DNA single-strand breaks (SSB) can be directly induced
by oxidative attack at the sugar-phosphate backbone or
indirectly during the course of repair of damaged bases
generated by both internal and external DNA damaging
agents such as oxygen free radicals, ionizing radiation and
alkylating agents (1). If left unrepaired, SSBs can be con-
verted into potentially lethal double-strand breaks (DSBs)
(1). SSBs often bear non-ligatable termini, such as
30-phosphate and 50-hydroxyl termini (2,3), which are
required to be converted respectively to 30-hydroxyl and
50-phosphate termini so as to facilitate downstream DNA
synthesis and ligation by DNA polymerase b and DNA
ligase III (1,4).
Human polynucleotide kinase (PNKP) is a DNA repair
enzyme that processes DNA termini (5,6). It contains
three domains: a forkhead-associated (FHA) domain, a
kinase domain and a phosphatase domain (5–7). The
latter two domains are responsible for the enzyme’s dual
cellular functions of phosphorylating 50-termini and
dephosphorylating 30-termini. PNKP has been shown to
play a critical role in several repair pathways including
base excision/single-strand break repair (BER/SSBR)
(4,8,9) and the nonhomologous end-joining (NHEJ)
repair pathway for DSB repair (10–12). Decreased expres-
sion of PNKP in A549 cell lines using siRNA silencing
gave rise to cells sensitized to a range of genotoxic
agents, most notably ionizing radiation and the
topoisomerase I inhibitor, camptothecin, a slower repair
rate of DNA strand breaks, and increased spontaneous
mutation frequency (13).
Unlike the phosphatase and kinase domains in PNKP,
the FHA domain of PNKP has no enzymatic activity.
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protein recognition motifs that are often found in regula-
tory proteins in the nucleus including kinases,
phosphatases and transcription factors (14,15). The
PNKP FHA domain has been shown to bind to the
DNA repair proteins XRCC1 and XRCC4 following
phosphorylation of the proteins by protein kinase CK2
(11,16).
XRCC1 is considered to be a scaﬀold protein primarily
involved in SSB repair (1,17,18), but may also play a role
in a newly-described DSB repair pathway (19,20). The
protein can bind to PNKP, DNA polymerase b and
DNA ligase III. Binding of XRCC1 to PNKP stimulates
PNKP’s enzymatic activities (8), and we have shown that
this is most likely due to enhanced protein turnover (21).
XRCC1 is rich in serine (Ser: 9.8%) and threonine (Thr:
4.6%) residues, which are the potential phosphorylation
sites in proteins. Loizou et al. (16) originally demonstrated
that XRCC1 can interact with the PNKP FHA domain
through a peptide sequence in XRCC1 phosphorylated by
CK2, and this interaction stimulates PNKP enzyme
activity even more than the interaction between PNKP
and non-phosphorylated XRCC1. Recently, Ali et al.
(22) synthesized a series of phospho-peptides based on
an XRCC1 phosphorylated segment (Tyr515–Glu526),
and demonstrated, using isothermal titration calorimetry
and co-crystallization methods, that there are two binding
sites in this peptide for the FHA domain of PNKP, and
that the phosphorylated peptide can bind two separate
FHA domains in tandem. Since there are potentially
more phosphorylation motifs for CK2 on XRCC1 the sit-
uation may be more complicated for the interaction of the
full-length proteins.
Therefore, in order to gain more insight into the
XRCC1-PNKP interaction, we examined XRCC1
phosphorylation by CK2 in vitro, its interaction with the
FHA domain of PNKP, and compared the inﬂuence of
phosphorylated versus non-phosphorylated XRCC1 on
the phosphatase and kinase activities of PNKP.
MATERIALS AND METHODS
Expression and puriﬁcation of proteins
XRCC1 and PNKP-XRCC1 cDNA cloned in pET16BXH
vector and PNKP cDNA cloned in pET16b were trans-
formed in Escherichia coli BL21 (DE3) for expression and
aﬃnity puriﬁcation following previously reported
procedures (6,23). The fractions containing high concen-
tration of each protein after aﬃnity puriﬁcation on
Ni–NTA beads were pooled and dialyzed against buﬀer
containing 50mM Tris (pH 7.5), 100mM NaCl, 5mM
MgCl2 and 1mM DTT and quantiﬁed using established
extinction coeﬃcients, "1%
280nm of 7.9 for XRCC1 (23) and
"1%
280nm of 12.2 for PNKP (24). The proteins were stored at
 80 C.
FHA and catalytic domains of PNKP—Human PNKP
cDNA with a 10  His tag was previously cloned between
Xba I and Bam HI restriction sites in the BlueScript
plasmid (21). To generate a construct encoding the FHA
domain, a stop codon and BamH1 restriction site were
introduced at the end of codon 130 using the
QuickChange site-directed mutagenesis kit (Stratagene,
La Jolla, CA). The modiﬁed construct was then digested
with Bam HI and Xba I, and the 497bp fragment corre-
sponding to the FHA domain was ligated into Bam HI/
Xba I cleaved pET16b (Novagen, Gibbstown, NJ). The
resultant plasmid encoding the FHA domain (from Met1
to Lys130 with a 10  His tag at the N-terminus) was
transformed into E. coli DE3 (BL21) pLysS (Novagen)
for protein expression following the protocol recom-
mended by Novagen. The protein was puriﬁed from the
E. coli lysate using Ni–NTA agarose beads (Qiagen,
Mississauga, ON) as directed by the manufacturer. The
recovered protein was dialyzed and concentrated using a
Millipore microconcentrator (Millipore, Etibicoke, ON)
and stored in buﬀer containing 50mM Tris pH 7.5,
100mM NaCl, 5mM MgCl2 and 1mM DTT at  80 C.
The 16.5kDa protein was quantiﬁed by the Bradford
assay (25), and shown to be detectable by both mono
and polyclonal anti-PNKP antibodies (Supplementary
Figure S1). The C-terminal (CT) catalytic kinase/
phosphatase domain (K141-G521) of PNKP was
subcloned and expressed in E. coli in a similar manner.
CK2—The cDNA of CK2a previously cloned in pGEX-
3X vector with an N-terminal GST tag (26) was trans-
formed into E. coli BL21 (DE3) for protein expression.
The cells were ﬁrst cultured at 37 C with continuous
shaking until the OD600 reached 0.6. Protein expression
was then induced by IPTG at 30 C for 3h. The cells were
then harvested at 8000rpm and 4 C for 15min, washed
with cold PBS, suspended in PBS containing 50mM PMSF
and subjected to sonication on ice for 5 30s. Triton
X-100 was added to the mixture to make the ﬁnal concen-
tration 1% Triton X-100, and the mixture was incubated
on ice with shaking for 15min followed by centrifugation
at 4 C to obtain the soluble supernatant. The GST-tagged
CK2a was then bound to glutathione–Sepharose 4B beads
(GE Healthcare, Baie d’Urfe, PQ) by incubating the lysate
with GSH beads for 1h on ice. The beads were then
washed with PBS containing 50mM PMSF, and the
protein was eluted with Tris–HCl buﬀer (50mM, pH
8.0) containing 10mM GSH. The fractions with the
highest concentration of CK2a were dialyzed against
buﬀer containing 50mM Tris–HCl (pH 7.5), 200mM
NaCl, 1mM EDTA and 50% glycerol three times at
4 C, quantitated by Bradford assay, and stored at
 80 C for further use.
In vitro phosphorylation of XRCC1 by CK2
Phosphorylation of XRCC1 by CK2 was carried out in
kinase buﬀer containing 50mM Tris (pH 7.5), 150mM
NaCl, 10mM MgCl2 and 0.1mM ATP. To follow the
phosphorylation, 1.5mg XRCC1 and 3.3pmol of
32P
labeled ATP were added to the vial containing kinase
buﬀer. Then 0.1mg CK2 (diluted immediately from the
stock using cold dilution buﬀer containing 1mg/ml BSA,
5mM MOPS pH 7.0 and 200mM NaCl) was added to the
vial. The reaction was then incubated at 30 C for up to
90min. Aliquots of the reaction mixture were sampled
at 0, 30, 60 and 90min, mixed with Laemmli buﬀer, and
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an SDS–PAGE gel to monitor the phosphorylation of
XRCC1.
To prepare phosphorylated XRCC1 (pXRCC1) for
further use, radio-labeled ATP was omitted while main-
taining the same ratio of XRCC1 and CK2 in the reaction
mixture. In this case, an elemental detector, i.e. inductively
coupled plasma mass spectrometer, was applied to
quantify the phosphate incorporated in the proteins.
After phosphorylation, the resultant reaction mixture
was incubated with 100ml GSH-Sepharose beads at 4 C
for 30min to remove the GST-tagged CK2a, and the
supernatant was collected for further use. To test the
level of phosphorylation, 50ml of the supernatant was
desalted into HPLC grade water using a BioSpin column
(Bio-Rad Laboratory, Mississauga, ON). One portion of
the resultant ﬁltrate was analyzed by inductively coupled
plasma mass spectrometry using scandium as an internal
calibrator and free ATP as an external calibrator. The
protein in the other portion of ﬁltrate was quantiﬁed
using the Bradford assay. The molar ratio of phosphate
to protein was then calculated based on the above
measurements.
Trypsin digestion of XRCC1
Phosphorylated XRCC1 was puriﬁed by 10% SDS–
PAGE, and stained with 0.1% Coomassie blue. After
destaining, the band with an apparent MW of  80kDa
was extracted and digested at 37 C overnight using
proteomics grade trypsin (Promega, Madison, WI) with
a mass ratio of trypsin to protein=1:50, according to
the protocol for in-gel digestion of protein previously
described (27). The resultant peptides were then mixed
with 2,5-dihydroxybenzoic acid (25mg/ml in 70%
acetonitrile and 1% H3PO4) in 1:1 ratio (v/v). One
microliter of the resultant peptide mixture was loaded
onto the MALDI plate for peptide analysis.
MALDI-TOF measurements of proteins and peptides
An Autoﬂex III MALDI-TOF mass spectrometer
(Bruker, Fremont, CA) was employed to analyze the
molecular weight of XRCC1 before and after
phosphorylation by CK2, and also for analyzing the
trypsin digestion products combined with peptide
mapping. For analysis of the full-length proteins,
XRCC1 and the phosphorylation reaction mixtures (con-
taining both pXRCC1 and CK2a) were ﬁrst desalted using
C8 ziptips (Millipore, Billerica, MA), mixed with sinapinic
acid, and loaded onto the MALDI probe for molecular
weight analysis. The instrument was calibrated using
standard BSA and its dimers. The molecular weight
accuracy was within 100ppm. For peptide analysis, a
standard peptide from Bruker was used for calibration
of the instrument, and the mass accuracy was generally
within 20ppm. Proteomics software such as PeptideMass
(http://www.expasy.org/) was applied to predict the theo-
retical peptides generated by trypsin digestion.
Co-immunoprecipitation of XRCC1 with PNKP and its
truncated domains
Non-phosphorylated XRCC1 (npXRCC1) or pXRCC1
(1.5mg) were separately mixed with the FHA domain of
PNKP at diﬀerent molar ratios in buﬀer containing
50mM Tris–HCl (pH 7.5), 100mM NaCl, 5mM MgCl2
and 1mM DTT, and incubated on ice for 30min. Anti-
XRCC1 polyclonal antibody (0.6mg, Santa Cruz Biotech,
Santa Cruz, CA) was added to the reaction vial, and
incubated on ice with continuous shaking for 2h.
Protein A Sepharose beads (10ml, GE Healthcare) were
then added to the reaction mixture, and the reaction
mixture was incubated on ice for another 2h. The beads
were washed three times with Tris buﬀer containing 0.1%
Tween-20 and the protein remaining bound to the beads
was eluted by boiling the beads in Laemmili buﬀer con-
taining 0.125M Tris–HCl, 4% SDS, 20% glycerol, 10%
2-mercaptoethanol and 0.004% bromphenol blue. The
resultant supernatant solution was subjected to 10%
SDS–PAGE and western blotting analysis using a
monoclonal anti-PNKP antibody (28), horseradish
peroxidase-conjugated goat anti-mouse IgG antibody,
and the ECL Plus western blot detection system (GE
Healthcare).
Steady-state ﬂuorescence spectroscopy
The interaction between p/npXRCC1 and PNKP and its
FHA and CT catalytic domains was studied using
acrylodan-labeled PNKP as described previously for
studying PNKP-XRCC1 interactions (21,23). The interac-
tion between pXRCC1 and single-stranded DNA was
studied using the intrinsic ﬂuorescence due to tryptophan
residues as described previously for npXRCC1 (23).
GraphPad Prism software (GraphPad Software Inc. La
Jolla, CA) was used for the analysis of binding data.
Circular dichroism spectroscopy
Far-UV CD measurements were performed with an
Olis DSM 17 CD spectropolarimeter (Bogart, GA) as
previously described (23).
Substrate preparation
HPLC puriﬁed single-strand oligonucleotides (Oligos 1–6)
with the sequences shown in Table 1 were synthesized
by Integrated DNA Technology (Coralville, IA). The
oligonucleotides were then annealed following the
scheme shown in Table 2. The annealed products were
puriﬁed on 8% native PAGE gels followed by ethanol
precipitation. The resultant double-stranded substrates
were resuspended in distilled water before use.
PNKP kinase and phosphatase assay using ﬂuorescent
substrates
We followed the protocol of Dobson and Allinson (29)
with minor modiﬁcations to simultaneously monitor the
kinase and phosphatase activities of PNKP. Brieﬂy,
substrate (80nM) was added to a buﬀer containing
80mM succinate (pH 5.5), 10mM MgCl2, 1mM DTT
and 0.1mM ATP followed by addition of 4nM PNKP.
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time point (0, 2, 5, 10 and 20min), 3ml aliquots were with-
drawn and mixed with 2  denaturing loading buﬀer,
incubated at 95 C for 5min and analyzed on a
polyacrylamide/urea gel. The gel was visualized using a
Typhoon 9400 or Typhoon Trio laser scanning system
(GE Healthcare). The image was then analyzed using
ImageQuant 5.2 or ImageQuant TL software (GE
Healthcare), and the data obtained were plotted using
Igor Pro software (WaveMetrics, Portland, OR).
Conventional PNKP kinase activity assay using
32P labeling
To examine the kinase activity of PNKP using
32P ATP
labeling assay, we applied the method reported previously
(21). Brieﬂy, 0.2nmol 24mer single-strand oligonucleotide
(Oligo 6, Table 1), cold ATP (0.4nmol) and 3.3pmol
[g-
32P] labeled ATP were added to 50ml reaction buﬀer,
followed by the addition of 0.5mg PNKP. The reaction
was then incubated at 37 C. At various times aliquots
were withdrawn, mixed with 2  denaturing loading
buﬀer, denatured, electrophoresed and visualized using
the Typhoon 9400 laser scanning system as described
above.
Inﬂuence of npXRCC1 and pXRCC1 on the dual
activities of PNKP
To test the impact of XRCC1 phosphorylation on the
PNKP activity, PNKP was ﬁrst used to process the
substrate for 20min as described above. After 20min,
5-fold molar excess of npXRCC1, pXRCC1, or BSA
was added to the reaction, and the reaction was allowed
to proceed for another 20min. The reaction mixture was
sampled at various times. Each aliquot was mixed with 2 
denaturing loading buﬀer and denatured for SDS–PAGE
analysis and laser scanning.
Eﬀect of competitive binding of FHA to pXRCC1 on
the dual activities of PNKP
PNKP, pXRCC1 or npXRCC1, and FHA in Tris buﬀer
were mixed at a molar ratio of 1:5:20 on ice for 15min.
The protein mixture was then added to the reaction vials
containing substrate in 80mM succinate (pH 5.5), 10mM
MgCl2, 1mM DTT and 0.1mM ATP and incubated at
37 C for 20min. An equal volume of 2  loading buﬀer
was added and the DNA was heat denatured at 95 C for
5min before urea–PAGE analysis and ﬂuorescence
imaging scanning.
RESULTS AND DISCUSSION
Characterization of XRCC1 phosphorylation and
identiﬁcation of phosphorylation sites of XRCC1 by
mass spectrometry
Using
32P-labeled ATP, we observed the phosphorylation
of XRCC1 by CK2 (Figure 1A) and calculated that the
degree of phosphorylation varied between experiments
with the molar ratio ranging between 4.5 and 6 phosphates
per XRCC1. Measurement by inductively coupled plasma
mass spectrometry (ICPMS) to selectively monitor phos-
phorus present in the protein yielded a similar molar ratio.
The phosphorylation of XRCC1 results in a molecular
mass increase in the protein by 80Da for the addition of
each phosphate group to the protein. Using MALDI-
TOF/MS to measure the molecular mass of the protein
following its phosphorylation, we observed that the
molecular mass of XRCC1 increased to 71.2kDa, which
is  400Da larger than non-phosphorylated XRCC1
(70.8kDa) (Figure 1B), indicating that an average of ﬁve
residues were phosphorylated by CK2, which was consis-
tent with the quantitative assay using ICPMS analysis.
Table 2. Schematic representation of model substrates
Component Annealing scheme
Nick Oligo1+Oligo2+Oligo3
Gap Oligo1+Oligo2+Oligo4
Overhang Oligo2+Oligo5
Table 1. Sequences of the oligonucleotides synthesized
Name Length Sequence
Oligo1 18mer 50-(6-FAM)TAGCATCGATCAGTCCTCp-30
Oligo2 21mer 50-GAGGTCTAGCATCGTTAGTCA(TAMRA)-30
Oligo3 39mer 50-TGACTAACGATGCTAGACCTCGAGGACTGATCGATGCTA-30
Oligo4 40mer 50-TGACTAACGATGCTAGACCTCTGAGGACTGATCGATGCTA-30
Oligo5 39mer 50-TGACTAACGATGCTAGACCTCATCCGTTCAGTACGTAGG-30
Oligo6 24mer 50-GGCGCCCACCACCACTAGCTGGCC-30
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protein, trypsin digestion followed by MALDI-TOF
peptide mapping was applied. We compared the mass
spectra obtained before and after phosphorylation by
CK2 (Figure 1C and D). With the MALDI linear
TOFMS mode, the m/z range of 3500–9000 was moni-
tored, in which peptides P1 (459–494) and P2 (503–546)
were found to shift to higher m/z after CK2
phosphorylation. Peptide P1 can be triply phosphorylated
with m/z increases of 80, 160 and 240, indicating that 3 of
4 potential sites (S461, S475, S485 and T488) have been
phosphorylated, among which only T488 is the conven-
tional motif for CK2 phosphorylation (16,30,31). Peptide
P2, can be tetraphosphorylated with m/z increases of 80,
160, 240 and 320, indicating that four potential sites (S518,
T519, T523 and S525) can all be phosphorylated, though
only S518 and T523 are typical CK2 sites. With reﬂective
TOFMS mode, we also monitored the mass spectrum at
the low m/z range, and found another peptide, P3
(401–427), was phosphorylated with a weak signal at
m/z of 3133 and a much more intense peak at 3149
(arising from oxidation of the methionine), which were
480m/z higher than the unphosphorylated peptide P1
(m/z=2652) and its oxidized form at m/z of 2668
(Figure 1D), indicating that six serine sites on this
segment were fully phosphorylated, with S408, S409,
S410 and S421 as the CK2 consensus sites, while S416
and S418 are atypical sites for CK2. Under our
conditions, we observed singly phosphorylated P1 and
triply phosphorylated P2 to be the most abundant
modiﬁcations. Our data showing multiple sites of
phosphorylation at the three peptide sites are in broad
agreement with those of Loizou et al. (16). In their
analysis of the phosphorylation of three peptides with
amino acid sequences corresponding to P1, P2 and P3,
these authors observed that the P2 peptide underwent
the most rapid phosphorylation by CK2. Furthermore,
XRCC1 immunoprecipitated from HeLa cells displayed
multiple phosphorylation (up to four residues) in the P1
peptide sequence and similarly up to four sites of
phosphorylation in the P2 peptide region, with the
largest signal arising from triple phosphorylation (16).
Thus our in vitro phosphorylation of XRCC1 appears to
closely reﬂect the in vivo phosphorylation proﬁle.
FHA domain of PNKP binds to pXRCC1 speciﬁcally
The interaction of the FHA domain of PNKP with non-
phosphorylated XRCC1 (npXRCC1) and CK2-
phosphorylated XRCC1 (pXRCC1) in vitro was ﬁrst
examined by immunoprecipitation. The complex
formed between the FHA domain and XRCC1 was
Figure 1. In vitro phosphorylation of XRCC1. (A)
32P-labeling demonstrating the phosphorylation of XRCC1 by CK2. (B) Linear MALDI-TOFMS
analysis demonstrating the molecular weight increase of XRCC1 after phosphorylation. The upper trace shows the spectrum for pXRCC1 and the
lower trace is for the npXRCC1. The peak with an m/z value of 66477 shows the BSA calibration standard. (C) Linear MALDI-TOFMS analysis of
the trypsin digestion products indicating multiple phosphorylation within peptide segments P1 (459–494) and P2 (503–546). Upper trace pXRCC1,
lower trace npXRCC1. (D) Reﬂective MALDI-TOFMS analysis of the trypsin digest indicating multiple phosphorylation of peptide segment P3
(401–427). Upper trace pXRCC1, lower trace npXRCC1.
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probed with an antibody to PNKP that recognizes an
epitope in the FHA domain (28). As shown in Figure
2A, a band at 16kDa was observed following
coincubation of the FHA domain and pXRCC1,
indicating tight binding of the FHA to pXRCC1. In
contrast, no FHA signal was detected following
immunoprecipitation of the mixture of npXRCC1 with
FHA, indicating that there is no discernable binding
between FHA and npXRCC1. When human A549 cell
lysate was incubated with increasing amounts of the
FHA domain and immunoprecipitated with anti-XRCC1
antibody, the FHA peptide was co-immunoprecipitated
(Figure 2B), indicating the presence of phosphorylated
XRCC1 in the A549 cells with similar properties to
XRCC1 phosphorylated in vitro.
Evidence for diﬀerent PNKP binding sites for
npXRCC1 and pXRCC1
In order to obtain quantitative data for the interaction
between the FHA domain and pXRCC1, we labeled the
single Cys residue (Cys-46) in the FHA domain with
acrylodan (AC). When FHA-AC was excited at 380nm,
the emission maximum occurred at 495nm, and addition
of pXRCC1 resulted in  50% AC ﬂuorescence
quenching. Titration of FHA-AC with pXRCC1 yielded
the relative ﬂuorescence intensity curve shown in
Figure 3A inset. The maximum quenching observed at
saturating dose of pXRCC1 was taken as 1, and the
quenching at diﬀerent concentrations of pXRCC1 was
plotted as the fraction bound versus pXRCC1 concentra-
tion (Figure 3A). Non-linear regression analysis of this
binding data yielded a Kd value for FHA-AC binding to
pXRCC1 of 3.5±0.5nM. In Figure 3B, log(F0 F/
F F1) is plotted against log[pXRCC1] to obtain the
stoichiometric relationship between the two proteins,
where F0, F and F1 are the ﬂuorescence intensities of
solutions of FHA-AC alone, FHA-AC in the presence
of various concentrations of pXRCC1, and FHA-AC
saturated with pXRCC1, respectively (32). This plot
yielded a slope of 1.08, indicating a 1:1 interaction
between pXRCC1 and FHA-AC domain. In contrast,
npXRCC1 addition had no signiﬁcant eﬀect on AC ﬂuo-
rescence ( 3% quenching), thus providing no evidence for
its binding to the FHA domain (data not shown).
The binding constant we obtained for the pXRCC1/
FHA domain interaction indicates considerably tighter
binding between the full length XRCC1 and FHA
domain than seen with short phosphorylated XRCC1-
based peptides and the FHA domain (22). For example,
the Kd value for binding of the triphosphorylated
peptide YAGSTDENTDSE (phosphorylated amino
acids underlined) to the FHA domain was 190nM. This
implies that other components of XRCC1 contribute to
the stabilization of the protein–protein interaction. In our
hands, we determined a 1:1 stoichiometry between the
two proteins in contrast to Ali et al. (22), who observed
a 1:2 stoichiometry for the phospho-peptide:FHA
domain complex. It is not clear if this diﬀerence in
stoichiometry is due to the diﬀerent species examined,
i.e. full length XRCC1 versus phospho-peptide or to the
diﬀerent modes of analysis, i.e. ﬂuorescence quenching
versus isothermal calorimetry.
The CT catalytic kinase/phosphatase domain (K141-
G521) of PNKP was similarly subcloned, expressed and
labeled with AC. The labeled protein was found to be
functionally active, retaining  90% of its kinase activity
(data not shown). When the labeled protein CT-AC was
excited at 380nm, the emission maximum was centered at
485nm. Addition of npXRCC1 resulted in partial
quenching of AC ﬂuorescence and amounted to  30%,
when the two proteins were mixed in a 1:1 molar ratio.
Fluorescence titration (Figure 3C) yielded a Kd value for
the binding of npXRCC1 to the CT domain of
43.0±3.0nM, in close agreement with the Kd value
obtained with the AC-labeled full length PNKP (PNKP-
AC) (21). The slope of the plot of log(F0 F/F F1)
versus log[pXRCC1] was 1.1 (Figure 3D) indicative of a
1:1 stoichiometric interaction between the proteins. In
contrast to the addition of npXRCC1, pXRCC1 induced
quenching of AC ﬂuorescence of only  8%, signifying
modest interaction between the two proteins. This level
of quenching was not suﬃcient to allow us to determine
a Kd value. Collectively, our data therefore indicate that
there appear to be two major modes of interaction
between PNKP and XRCC1: a high aﬃnity FHA and
pXRCC1 mediated interaction and another, lower
aﬃnity, interaction that is not dependent on
phosphorylation and involves XRCC1 binding to the CT
catalytic domain of PNKP.
To further conﬁrm binding of npXRCC1 to the PNKP
catalytic domain, we analyzed the PNKP-CT/npXRCC1
interaction by far-UV circular dichroism. Typical CD
spectra of the two individual proteins are shown in
Figure 2. The FHA domain of PNKP can interact with XRCC1
phosphorylated in vitro by CK2 and in A549 cell lines.
(A) Phosphorylated XRCC1 (pXRCC1) and non-phosphorylated
XRCC1 (npXRCC1) was incubated with the FHA domain in diﬀerent
molar ratios and then immunoprecipitated. The ﬁgure shows the results
of western blots to determine if the FHA domain co-precipitated with
the XRCC1 proteins. (B) Co-immunoprecipitation of the FHA domain
after incubation with A549 cell lysate and immunoprecipitation with
anti-XRCC1 antibodies, indicating the presence of phosphorylated
XRC1 in A549 cells.
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CD bands centered  209 and 218nm, indicating the
presence of a-helical organization. Analysis of the CD
spectra according to Chen et al. (33), revealed PNKP-
CT to possess  30% a-helix and  30% b-structure,
with the remaining  40% representing random structure,
while XRCC1 possesses  35% a-helix and  30%
b-structure and  35% random structure. CD
measurements can be applied to study protein–protein
interactions. Since the ellipticity is an additive parameter,
one can generate the theoretical CD spectrum for a
mixture of non-interacting proteins by adding together
the spectra of individual proteins and this spectrum can
be compared to that observed experimentally to see if the
interaction has induced any conformational change. The
far-UV CD spectrum obtained for PNKP-CT:npXRCC1
complex (1:1 molar ratio) is shown in Figure 4C along
with the theoretical spectrum. The experimentally
observed ellipticity values deviate from the theoretical
values particularly in the 209 and 218nm wavelength
regions, demonstrating that an interaction between these
two proteins has produced a conformational change. For
instance, the diﬀerence between the observed and the the-
oretical ellipticity value at 218nm was  2600degcm
2/
dmol, while the experimental error in these measurements
is only ±300degcm
2/dmol. Analysis of the CD spectrum
of the PNKP-CT:npXRCC1 complex yielded  23%
a-helix and  32% b-structure and random structure
accounted for  45%. Comparison of the secondary struc-
ture of the complex with the secondary structure of the
individual proteins suggests that the interaction between
PNKP-CT and XRCC1 resulted in an increase in the
random structure at the expense of the a-helical structure.
Binding of pXRCC1 to DNA
We have previously obtained the Kd value for npXRCC1
binding to single-stranded DNA (45mer oligonucleotide)
by measuring the quenching of the intrinsic Trp ﬂuores-
cence of the protein at 340nm following excitation
at 295nm as a function of DNA concentration (21,23).
As shown in Figure 5, we used the same approach to
determine if phosphorylation of XRCC1 alters its
aﬃnity for DNA. A representative plot of relative ﬂuores-
cence intensity versus the concentration of DNA is
shown (inset). Non-linear regression analysis of the
binding data revealed unimodal binding with a Kd value
of 0.80±0.10mM, which represents  3-fold lower aﬃn-
ity compared with the binding of npXRCC1
(Kd=0.26±0.02mM) (23). The DNA binding domain
of XRCC1 has been mapped to the N-terminal domain
(17,34). It remains to be determined if phosphorylation of
the CT domain reduces the aﬃnity of XRCC1 for DNA
due to altered protein conformation or possibly charge
repulsion between the multiply phosphorylated protein
and DNA backbone.
Figure 3. Interaction of XRCC1 with diﬀerent domains of PNKP. (A) Fluorescence titration of the AC labeled FHA domain versus pXRCC1.
FHA-AC (0.065mM) was excited at 380nm and the relative ﬂuorescence (Rel.Fluor) intensities were monitored at 480nm (see inset). The fraction
bound versus pXRCC1 concentration is plotted. (B) Sample plot of ﬂuorescence data from titration with pXRCC1. F0, F and F1 are the relative
ﬂuorescence intensities at 480nm of FHA-AC alone, FHA-AC in the presence of a given concentration of pXRCC1, and FHA-AC saturated with
pXRCC1, respectively. The plot is according to Chipman et al. (32). (C) Fluorescence titration of the AC labeled PNKP CT-domain versus
npXRCC1. CT-AC (0.3mM) was excited at 380nm and the relative ﬂuorescence (Rel. Fluor) intensities were monitored at 480nm (see inset).
The fraction bound versus npXRCC1 concentration is plotted. (D) Analysis of the ﬂuorescence titration data of CT-AC with npXRCC1 as described
for FHA-AC in panel B.
516 Nucleic Acids Research, 2010,Vol. 38,No. 2Analysis of the dual activities of PNKP on nicked and
gapped substrates
We adopted an assay recently developed by Dobson and
Allinson (29) that utilizes a double-ﬂuorophore labeled
substrate to measure the kinase and phosphatase activity
of PNKP simultaneously. In agreement with Dobson and
Allinson, we observed that PNKP showed a faster
reaction rate in processing the 30-phosphate terminus
than processing the 50-OH terminus in a substrate with
a nick (Figure 6A and B). Examination of a series of
diﬀerent substrates indicated a marked variation in the
eﬃciency of processing of the termini (Figure 7A–D).
With the molar ratio of PNKP to substrate set at 1:15
and reducing the quantity of enzyme 4-fold from the
previous experiment in order to monitor the reaction
over a longer period of time, we observed that PNKP
removed the 30-terminal phosphate from the 1-nucleotide
(1-nt) gap substrate more eﬃciently than from the nicked
substrate. After 5min incubation, the phosphatase
reactions reached equilibrium, with more than 95% of
Figure 4. Protein analysis by circular dichroism showing interaction of
the catalytic domain of PNKP with non-phosphorylated XRCC1. Far-
UV CD spectra of npXRCC1 (A) and PNKP-CT (B) in 50mM Tris–
HCl, pH 7.5, 100mM NaCl, 5mM MgCl2.( C) Experimentally
observed (ﬁlled square) and theoretical (ﬁlled triangle) CD spectra of
the PNKP-CT:XRCC1 complex. For the theoretical spectrum the
proteins are assumed to be non-interacting.
Figure 6. Simultaneous monitoring of kinase and phosphatase
activities of PNKP using the ﬂuorescence-based assay of Dobson and
Allinson (29). A nicked DNA substrate (80nM) bearing a 30-phosphate
(P) and 50-hydroxyl group (OH) was incubated with 0.1mM ATP and
20nM PNKP. The products of the reaction, i.e. FAM-labeled 18mer
(30-phosphatase product) and TAMRA-labeled p21mer (50-kinase
product) were monitored by gel electrophoresis (A) and quantiﬁed (B)
over time.
Figure 5. Binding of pXRCC1 to DNA. Fluorescence titration of
pXRCC1 with a 45mer single-stranded oligonucleotide. pXRCC1
(0.4mM) in 50mM Tris–HCl (pH 7.5), 100mM NaCl and 5mM
MgCl2 was excited at 295nm, and the intrinsic ﬂuorescence intensity
was monitored as a function of DNA concentration at 340nm (see
inset). The fraction bound (i.e. relative ﬂuorescence quenching) versus
ligand concentration is plotted.
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removal of the phosphate from the nick substrate. In
contrast, the kinase reaction tended to reach equilibrium
after 10min reaction. Up to 60% of the 1-nt gap substrate
was phosphorylated, while processing of the nick substrate
was <5%, making it diﬃcult to quantify. Thus, although
PNKP has previously been shown to preferentially
phosphorylate SSB termini rather than sterically more
accessible blunt-ended DSB termini (7,35,36), steric
factors are probably responsible for the higher reactivity
towards a 1-nt gapped substrate than a substrate with a
nick. Interestingly, however, for the substrate with an
extended recess, the level of 50-phosphorylation showed
intermediate activity reaching  25% under the same
conditions, implying that the PNKP kinase activity is
enhanced by the presence of a DNA strand downstream
to the site of phosphorylation.
Stimulation of PNKP enzyme activity by npXRCC1
and pXRCC1
The inﬂuence of XRCC1 on phosphatase activity of
PNKP was examined using the nick substrate. The rate
of product accumulation decreased over time and reached
a plateau at  10min (Figure 8A). When 5-fold molar
excess of npXRCC1 or pXRCC1 was added to the
reaction after 20min incubation, it led to the restimulation
of the phosphatase activity and dephosphorylated product
continued to accumulate to another plateau. pXRCC1
appeared to enhance the PNKP phosphatase to a greater
extent than npXRCC1. Addition of BSA failed to stimu-
late PNKP, indicating that the stimulatory eﬀect of
pXRCC1 and npXRCC1 was not the result of non-
speciﬁc enzyme stabilization.
The eﬀect of XRCC1 phosphorylation on PNKP kinase
activity was tested under limited enzyme concentration
using a single-stranded 24mer oligonucleotide containing
a5 0-OH group (Figure 8B). Addition of npXRCC1
increased the product yield by a further 40%, which is
consistent with our previous report (21). Addition of
pXRCC1, on the other hand, more than doubled the
level of phosphorylated oligonucleotide. The results
above indicated that both npXRCC1 and pXRCC1 can
re-activate and enhance the turnover rate of PNKP.
Moreover, pXRCC1 can enhance PNKP turnover rate
more eﬃciently than npXRCC1.
Figure 7. Comparison of PNKP activity with diﬀerent substrates. Substrates (80nM) bearing a nick (A), recessed 50-terminus (B) and 1-nucleotide
gap (C) were incubated with 4nM PNKP and 0.1mM ATP. (D) Plot of percentage of product accumulated over time. (open circle)
30-dephosphorylation product from the nick substrate; (open square) 30-dephosphorylation product from the gap substrate; (ﬁlled square)
50-phosphorylation product from the gap substrate; (ﬁlled triangle) 50-phosphorylation product from the recessed substrate. The data points represent
the mean of three individual determinations and the error bars show the standard deviation from the mean.
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We made use of the tight binding of pXRCC1 to the FHA
domain to determine whether the stimulation of PNKP
activity by pXRCC1 is dependent on interaction with
the FHA domain. PNKP was preincubated with
npXRCC1 or pXRCC1 at 4 C for 15min, in the
presence or absence of the FHA domain, and was then
added to the nick substrate using a molar ratio of PNKP
to substrate of 1:10. As shown in Figure 9, in the presence
of pXRCC1, but absence of the FHA domain, kinase
activity was enhanced from 3.6 to 17.5%, and
phosphatase activity was enhanced from 45 to 67%
compared to PNKP alone. However, pre-incubation of
PNKP with pXRCC1 in the presence of the FHA
domain almost completely inhibited pXRCC1 stimulation
of both the kinase and phosphatase activity of PNKP. In
contrast, co-incubation of the PNKP-npXRCC1 complex
with the FHA domain did not reduce the stimulatory
action of npXRCC1.
CONCLUSION
XRCC1 is known to stimulate the activity of PNKP (8).
One potential explanation has been that XRCC1, in its
capacity as a scaﬀold protein, recruits PNKP to the site
of damage although there is evidence to suggest that the
opposite may be the case, i.e. that PNKP recruits
Figure 8. Stimulation of PNKP end-processing activities by pXRCC1 and npXRCC1. (A) The eﬀect of pXRCC1 and npXRCC1 on PNKP
phosphatase activity. The ﬂuorescently labeled nick substrate (80nM) was incubated with 4nM PNKP and 0.1mM ATP for 20min and then
divided into four aliquots. Three of the aliquots were supplemented with 20nM pXRCC1, npXRCC1 or BSA and the fourth received buﬀer only.
The reactions were followed for a further 20min. (B) The eﬀect of both pXRCC1 and npXRCC1 on the kinase activity of PNKP acting on the 50OH
group of a single-stranded 24-mer, using the same conditions as described above. The data were obtained from three individual determinations and
the error bars represent the standard deviation from the mean.
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previously shown that XRCC1 stimulates the dissociation
of PNKP from 50-phosphorylated DNA, thereby
increasing PNKP turnover. Here we have shown that
XRCC1 similarly stimulates the PNKP phosphatase
activity and that an elevation of the rate of enzyme
turnover is at least partly responsible for the increased
stimulation aﬀorded by CK2 phosphorylated XRCC1.
However, even though phosphorylated and non-
phosphorylated XRCC1 both appear to stimulate PNKP
by a similar mechanism, we have demonstrated that the
interaction between pXRCC1 and PNKP diﬀers substan-
tially from that between npXRCC1 and PNKP. The
former is totally dependent on XRCC1 binding to the
FHA domain while the latter involves XRCC1 interaction
with the catalytic domain. Although the bulk of XRCC1
in human cells appears to be phosphorylated, it is not
clear if the key site for interaction with the FHA
domain is fully phosphorylated (16). Furthermore, there
appears to be a requirement for additional
phosphorylation of XRCC1 by CK2 for rapid repair of
SSBs immediately after cellular exposure to oxidative
damaging agents such as H2O2 (4,16). It is therefore
possible that the enhanced CK2 phosphorylation of
XRCC1 is required for cells to cope in a timely fash-
ion with a major challenge to the repair machinery (4),
while under normal circumstances unstressed cells
make use of non-phosphorylated XRCC1 or XRCC1
with a limited level of phosphorylation to stimulate
PNKP activity by the alternative mode of interaction to
handle the comparatively low level of DNA damage
produced endogenously.
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